Neurocrine Biosciences | NBIX - 债务利息支出



金融业
股票价格
USD
资产
USD 5.36B
现金及等价物
USD 332.4M
销售成本
USD 39.4M
流动资产
USD 1.64B
流动负债
USD 874.5M
债务
USD 406.2M
EBIT
USD 219.9M
EBITDA
USD 193.3M
员工
1.8K
EPS每股收益
USD 2.85
股本和储备
USD 3.69B
销售毛利
USD 800.7M
债务利息支出
USD 1.1M
贷款资金
USD 169.5M
市值
USD 15.48B
净收入
USD 144.4M
营业费用
USD 739.1M
营业利润
USD 219.9M
普通股股本
USD 100.55M
PE价格收益
22.1
税前利润
USD 246.8M
销售收入
USD 959M
销售和管理费用
USD 383.1M
股票
USD 104.2M
贸易债权人
USD 691.3M
应收帐款人
USD 887M


债务利息支出 更改 日
AbbVie USD 645M 69M 2026-03
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
ALKERMES USD 25.92M 5.03M 2026-06
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Amgen USD 95.64B 94.98B 2026-06
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 63.29M 48.34M 2026-06
Cytokinetics USD 34.83M 1.5M 2026-06
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Exelixis USD 23.4M 3.9M 2023-09
Gilead Sciences USD 247M 7M 2026-06
Halozyme Therapeutics USD 5.59M 80K 2026-06
Incyte USD 582K 13K 2026-06
Ionis Pharmaceuticals USD 18M 1000K 2026-06
Nektar Therapeutics USD 7.94M 1.83M 2026-03
Neurocrine Biosciences USD 1.1M 0 2024-03
Pfizer USD 667M 4M 2026-06
Prothena USD 302.58M 47.32M 2026-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Repligen USD 5.66M 85K 2026-06
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Sarepta Therapeutics USD 21.51M 205K 2026-06
Teva Pharmaceutical Industries USD 195M 21M 2026-06
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
Vertex Pharmaceuticals USD 3.3M 0 2025-12